- Home
- ATRA vs RFL Comparison
ATRA vs RFL Comparison
Compare ATRA & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRA
- RFL
- Stock Information
- Founded
- ATRA 2012
- RFL 2017
- Country
- ATRA United States
- RFL United States
- Employees
- ATRA N/A
- RFL N/A
- Industry
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- RFL Real Estate
- Sector
- ATRA Health Care
- RFL Finance
- Exchange
- ATRA Nasdaq
- RFL Nasdaq
- Market Cap
- ATRA 65.1M
- RFL 55.3M
- IPO Year
- ATRA 2014
- RFL N/A
- Fundamental
- Price
- ATRA $11.40
- RFL $1.92
- Analyst Decision
- ATRA Buy
- RFL
- Analyst Count
- ATRA 6
- RFL 0
- Target Price
- ATRA $26.50
- RFL N/A
- AVG Volume (30 Days)
- ATRA 77.5K
- RFL 30.6K
- Earning Date
- ATRA 11-12-2024
- RFL 01-03-2025
- Dividend Yield
- ATRA N/A
- RFL N/A
- EPS Growth
- ATRA N/A
- RFL N/A
- EPS
- ATRA N/A
- RFL N/A
- Revenue
- ATRA $100,439,000.00
- RFL $697,000.00
- Revenue This Year
- ATRA $1,346.63
- RFL N/A
- Revenue Next Year
- ATRA N/A
- RFL N/A
- P/E Ratio
- ATRA N/A
- RFL N/A
- Revenue Growth
- ATRA 2111.34
- RFL 151.62
- 52 Week Low
- ATRA $6.50
- RFL $1.29
- 52 Week High
- ATRA $39.50
- RFL $2.50
- Technical
- Relative Strength Index (RSI)
- ATRA 51.71
- RFL 53.58
- Support Level
- ATRA $9.13
- RFL $1.71
- Resistance Level
- ATRA $13.64
- RFL $1.92
- Average True Range (ATR)
- ATRA 0.96
- RFL 0.10
- MACD
- ATRA -0.27
- RFL -0.00
- Stochastic Oscillator
- ATRA 50.33
- RFL 84.00
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.